Global Down Syndrome

Fall 2015

Issue link: https://viewer.e-digitaledition.com/i/618504

Contents of this Issue

Navigation

Page 9 of 31

SCIENCE SNPS NEW INSIGHTS INTO GIRK The dorsal hippocampus plays a critical role in cognitive function, and in particular, spatial and contextual learning. This part of the brain is also heavily influenced by G protein-gated inwardly rectifying potassium ion (GIRK) channels, but whether GIRK channels play a role in cognitive function has never been well understood. Using mouse models, researchers from the University of Minnesota and The Scripps Research Institute determined that a subset of GIRK channels, GIRK2, are necessary for learning, and their research revealed that abnormalities in GIRK2 channels could lead to cognitive dysfunction. This research may illuminate strategies to develop therapeutic modalities to improve cognition in individuals with Downsyndrome. Biological Psychiatry, November 2015 VACCINES AND DOWN SYNDROME Individuals with Down syndrome naturally have lower levels of switched memory B cells, which are generated after a person receives a vaccine. This population is also particularly susceptible to vaccine-preventable respiratory infections, particularly influenza and pneumonia. To study the effect of the seasonal influenza vaccine in people with Down syndrome, Italian scientists gave 15 children with Down syndrome and their typical siblings the influenza vaccine and then monitored their immune responses. After immunization, children with Down syndrome generated much fewer switched memory B cells than their siblings, as the scientists expected. The authors recommend developing special immunization strategies for individuals with Down syndrome, similar to those strategies developed for other groups dubbed "high-risk." They added that currently, people with Down syndrome are not included in populations designated as "high-risk." Vaccines, October 2015 A BETTER NIGHT'S SLEEP Individuals with Down syndrome are at an increased risk of both forms of sleep apnea: obstructive sleep apnea (OSA), in which the airways become blocked during sleep, and central sleep apnea (CSA), in which the brain's messages to the muscles that control breathing are interrupted. Both conditions cause breathing to stop and start repeatedly during sleep. A recent study from Children's Hospital of Pittsburgh involving 113 children with Down syndrome with an average age of 5.5 years old, found that adenotonsillectomy, a treatment generally reserved only to correct OSA, also improved sleep scores in those children suffering from CSA. Otolaryngology Head and Neck Surgery, June 2015 longitudinal study conducted in typical, elderly adults to identify Alzheimer's disease biomarkers. The goal of this research is to determine how and when the changes that lead to dementia occur and to create nationwide imaging protocols so all researchers obtain information in the same way. "People with Down syndrome comprise the world's largest population of people who are predisposed to Alzheimer's disease," Dr. Rafii said. "If we can determine the trajectory of Alzheimer's disease, we may be able to create drugs that disrupt that trajectory." Cognitive testing, blood tests, magnetic resonance imaging, and positron emission tomography scans that look for characteristic amyloid plaques and neurofibrillary tangles are among the diagnostic strategies that will be explored to help identify biomarkers. A white paper and position statement from discussions at the workshop are currently in development to outline imaging and other testing protocols that will serve as a template for future research. Researchers are also developing a biorepository to house data compiled during the study and are partnering with NICHD's DS-Connect®: The Down Syndrome Registry to recruit eligible study participants and disseminate information about Alzheimer's disease and Down syndrome. "To accelerate research, we need participation from adults with Down syndrome," Dr. Sabbagh said. "The cross-talk taking place between scientists studying Alzheimer's disease and those studying Down syndrome ultimately benefits both communities." For more information about ongoing research efforts, visit globaldownsyndrome.org/crnic-institute. AN INTERNATIONAL PARTNERSHIP In 2016, a multicenter study testing a potential vaccine for Alzheimer's disease will launch in the United States. The study is funded by the National Institutes of Health and sponsored by the LuMind Research Down Syndrome Foundation and AC Immune, a biopharmaceutical company located in Switzerland. According to AC Immune, the vaccine, known as ACI-24, is designed to stimulate the production of antibodies that target the amyloid beta plaques that are part of Alzheimer's disease pathology and contribute to dementia. The vaccine is currently being tested in typical populations through phase I and II clinical trials, and researchers will administer the vaccine to adults with Down syndrome to see if it is effective at reducing Alzheimer's disease-related dementia. CONTINUED FROM PAGE 8 FALL2015 DOWN SYNDROME WORLD 10

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Fall 2015